Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
Sponsor: Indiana University
Summary
Oropharyngeal squamous cell carcinoma (OPSCC), commonly known as throat cancer or tonsil cancer, has seen a dramatic rise in incidence over the last twenty years. There are two types of OPSCC: human papillomavirus-positive (HPV+) and human papillomavirus-negative (HPV-). People with OPSCC, regardless of their type, typically receive standard treatment with a combination of chemotherapy, radiation therapy, and surgery. Due to the intensity of standard treatment, survivors may experience unwanted long-term side effects. The goal of this research study is to see if intensifying (stopping or scaling back) treatment still provides the same, or perhaps even better, results when compared to standard treatment.
Official title: Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
83
Start Date
2022-05-12
Completion Date
2026-04
Last Updated
2025-05-02
Healthy Volunteers
No
Conditions
Interventions
44 doses of radiation
Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.
54 doses of radiation
Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.
Locations (2)
IU Health Joe and Shelly Schwarz Cancer Center
Carmel, Indiana, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States